Aimmune Therapeutics (Nasdaq: AIMT), a USA-based biopharma company developing treatments for life-threatening food allergies, has appointed Daniel Adelman its chief medical officer.
Dr Adelman is a renowned allergist and immunologist who spent seven years as chief medical officer at Alvine Pharmaceuticals, a privately-held US biotech focused on autoimmune and inflammatory diseases, particularly celiac disease.
He held the same role during five years at US pharma Sunesis Pharmaceuticals (Nasdaq: SNSS) and previously worked in various positions at Pharmacyclics and Genentech.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze